Skip to main content
. 2017 Oct 26;292(51):21102–21116. doi: 10.1074/jbc.M116.774836

Figure 4.

Figure 4.

Mensacarcin induces activation of caspase-3 and -7 in a cell type–specific manner in melanoma. Shown is the concentration–response relationship for mensacarcin-induced caspase-3/7 activation in SK-Mel-28 and SK-Mel-5 cells and HCT-116 after 12-h (A) and 24-h (B) exposure to mensacarcin (0.5, 2, 10, and 50 μm), vehicle (DMSO), or the positive control staurosporine (10 μm). We also tested the broad-spectrum caspase inhibitor Z-VAD-FMK alone (10 μm) and in combination with mensacarcin (0.5, 2, 10, and 50 μm), respectively. In all cases, the caspase-activating activity of mensacarcin was attenuated by Z-VAD-FMK. Caspase-3/7 activity was measured at the end of each treatment using a luminescence-based assay coupled with automated luminescence detection. Scatter plots represent mean ± S.D. (error bars) of triplicates (n = 3). *, p < 0.1; **, p < 0.01; ***, p < 0.001 mensacarcin versus DMSO treatment.